In addition, the will contract with the National Academy's Institute of Medicine to review the drug safety system and assess how it can learn more about potential harmful side effects before the drugs become widely used.
These drugs remain on the market in the absence of any evidence linking them to heart attacks and strokes.
Many analysts and doctors believe Arcoxia will only be approved after that study is completed and it demonstrates the drug doesn't increase the risk of heart attacks and strokes The 7,111-patient trial that was presented Tuesday at the American College of Rheumatology's annual meeting in
